3 PLUS Biotech Stocks Set To Soar Under Republican
Post# of 2218
(Total Views: 83)
Posted On: 05/05/2017 3:47:24 PM
3 PLUS Biotech Stocks Set To Soar Under Republican Leadership
November 30, 2016 | By Bret Jensen
After being the market’s whipping boy for the last year, the biotech sector looks ready to rebound under a pro-business White House. Already, many stocks have shot up over 50%, but Bret Jensen shares three today that still have plenty of upside backed up by strong products already on the market.
The biotech sector has seen a remarkable turnaround in November. The sector posted its best weekly gain since 2000 in what can only be called a “Yuge” post-election rally. Both the biotech and pharma industries were dreading the prospect of a clean electoral sweep of Congress and the White House by the Democrats. This would have most likely brought the wrath of Senators Warren and Sanders down upon these areas of the economy and markets. The resulting additional regulation and legislation would have been detrimental to growth, not to mention innovation in these segments of the economy. Both sectors sold off hard in October
What a difference a month makes. Politics did bring a clean sweep but for Republicans, which seemed the least likely of all political outcomes days into the actual election. After the post-election rally, we did see some consolidation and slight profit taking as one would expect after such a quick and unexpected rise. However, sentiment has shifted to a much more positive stance on the biotech sector after over a year of vastly underperforming in the overall market.
November 30, 2016 | By Bret Jensen
After being the market’s whipping boy for the last year, the biotech sector looks ready to rebound under a pro-business White House. Already, many stocks have shot up over 50%, but Bret Jensen shares three today that still have plenty of upside backed up by strong products already on the market.
The biotech sector has seen a remarkable turnaround in November. The sector posted its best weekly gain since 2000 in what can only be called a “Yuge” post-election rally. Both the biotech and pharma industries were dreading the prospect of a clean electoral sweep of Congress and the White House by the Democrats. This would have most likely brought the wrath of Senators Warren and Sanders down upon these areas of the economy and markets. The resulting additional regulation and legislation would have been detrimental to growth, not to mention innovation in these segments of the economy. Both sectors sold off hard in October
What a difference a month makes. Politics did bring a clean sweep but for Republicans, which seemed the least likely of all political outcomes days into the actual election. After the post-election rally, we did see some consolidation and slight profit taking as one would expect after such a quick and unexpected rise. However, sentiment has shifted to a much more positive stance on the biotech sector after over a year of vastly underperforming in the overall market.
(0)
(0)